An observational study in AML, Adult, sponsored by French Innovative Leukemia Organisation. Recruiting at 27 sites in France. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by French Innovative Leukemia Organisation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation — 4 open to participants now, 7 under way, none of them phase 3. Leukemia, Myeloid, Acute · French Innovative Leukemia Organisation.
Among the 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation, this one is the only one that started in 2015, is one of 5 observational ones, and was the 15th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →4 of the 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation are open now, in 1 country. Recruiting first, the newest first:
French Innovative Leukemia Organisation · Sites in France
Ages 18+
French Innovative Leukemia Organisation · Sites in France
Ages 18+
French Innovative Leukemia Organisation · Sites in France
Ages 55+
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 110 across the 11 interventional studies, 230 across the 5 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
French Innovative Leukemia Organisation is the lead sponsor of 59 studies on the registry; 9 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Leukemia, Myeloid, Acute by French Innovative Leukemia Organisation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This observational epidemiological study targets patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive receive intensive induction therapy as defined by the group. The main aim of the study is to determine the epidemiological characteristics of AML patients, both clinically and biologically, and to correlate these to their outcome. The incidence of AML increases with age, exponentially after the age of 50, giving a median age at diagnosis of close to 70 years, with over half of patients half of patients are over 60 at diagnosis. The principle of treatment as in younger patients, is based on trying to achieve complete remission (CR). remission (CR). Observed complete remission rates range from 38 to 70%. Long-term survival of elderly subjects remains limited, at around 10 to 15%, despite the various types of consolidation tried out in recent years.
years. However, intensive chemotherapy remains the preferred option for initial treatment of these hematological diseases when general condition and comorbidities allow. As shown by Swedish registry studies, it is associated with improved life expectancy.
The proportion of patients who can receive intensive initial treatment is not well known in France, probably varies widely from one region to another, and certainly decreases with increasing age. Only the registry studies currently underway will enable us to assess this precisely.
patients aged 60 and over with de novo or secondary acute myeloblastic leukemia suitable for intensive induction therapy, as defined by the group's recommendations
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
describe the initial characteristics of Acute myeloid leukemia (AML) in patients aged 60 years and older
Values for leukocytosis, blasts, neutrophils, and platelets (in /mm3)
Time frame: at diagnosis (from first results related to AML until AML diagnosis) 3 months
describe the initial characteristics of Acute myeloid leukemia (AML) in patients aged 60 years and older
the cytogenetic pronosis according ELN criteria
Time frame: at diagnosis (from first results related to AML until AML diagnosis) 3 months
Describe first line AML treatment received
type of treatment
Time frame: 12 months
characterize the Overall survival (OS)
defined as the time from date of initiation of chemotherapy to date of death due to any cause. Patients still alive or lost to follow up will be censored at the time they were last known to be alive
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2015 (actual). Primary completion is estimated for Jan 2030, 180 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Innovative Leukemia Organisation